Follow-up liver stiffness measurements after liver resection influence oncologic outcomes of hepatitis-b-associated hepatocellular carcinoma with liver cirrhosis

Jung Il Lee, Hyun Woong Lee, Seung Up Kim, Sang Hoon Ahn, Kwan Sik Lee

Research output: Contribution to journalArticle

Abstract

The severity of liver fibrosis can be noninvasively evaluated by measuring liver stiffness (LS) using transient elastography. This study aimed to evaluate the prognostic value of achieving low liver stiffness measurement (LSM) in patients with cirrhosis confirmed from the resected liver due to hepatocellular carcinoma (HCC). A total of 184 patients that received curative surgery for HCC related to the hepatitis B virus at Barcelona Clinic Liver Cancer stage 0–A, and had a METAVIR fibrosis score of 4 were investigated. LSM significantly decreased after antiviral therapy during follow-up (p = 0.001), and achieving LSM ≤8 kilopascal (kPa) suggested a reduced risk of late recurrence (>12 months) (hazard ratio (HR), 0.519; 95% confidence interval (CI), 0.307–0.877; p = 0.014). Older age at surgery (≥45 years) and multiple HCC nodules predicted an increased risk of late recurrence (HR, 3.270; 95% CI, 1.296–8.251; p = 0.012; and HR, 3.146; 95% CI, 1.396–7.089; p = 0.006). Decreased LSM also suggested decreased mortality (HR, 0.251; 95% CI, 0.086–0.756; p = 0.045) along with baseline low aspartate aminotransferase-to-platelet ratio index (APRI) score (<1.5) (HR, 0.251; 95% CI, 0.086–0.759; p = 0.041). Having early HCC recurrence (HR, 9.416; 95% CI, 3.566–24.861; p < 0.001) and microvascular tumor invasion (HR, 3.191; 95% CI, 1.188–8.568; p = 0.021) predicted increased mortality. Among HCC patients with liver cirrhosis under antiviral therapy, achieving low LSM (≤8 kPa) predicted reduced late HCC recurrence.

Original languageEnglish
Article number425
JournalCancers
Volume11
Issue number3
DOIs
Publication statusPublished - 2019 Mar

Fingerprint

Liver Cirrhosis
Hepatitis
Hepatocellular Carcinoma
Confidence Intervals
Liver
Recurrence
Antiviral Agents
Fibrosis
Elasticity Imaging Techniques
Mortality
Liver Neoplasms
Aspartate Aminotransferases
Hepatitis B virus
Blood Platelets
Therapeutics
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{4ef5b960b4a24a73bf36133017016c1d,
title = "Follow-up liver stiffness measurements after liver resection influence oncologic outcomes of hepatitis-b-associated hepatocellular carcinoma with liver cirrhosis",
abstract = "The severity of liver fibrosis can be noninvasively evaluated by measuring liver stiffness (LS) using transient elastography. This study aimed to evaluate the prognostic value of achieving low liver stiffness measurement (LSM) in patients with cirrhosis confirmed from the resected liver due to hepatocellular carcinoma (HCC). A total of 184 patients that received curative surgery for HCC related to the hepatitis B virus at Barcelona Clinic Liver Cancer stage 0–A, and had a METAVIR fibrosis score of 4 were investigated. LSM significantly decreased after antiviral therapy during follow-up (p = 0.001), and achieving LSM ≤8 kilopascal (kPa) suggested a reduced risk of late recurrence (>12 months) (hazard ratio (HR), 0.519; 95{\%} confidence interval (CI), 0.307–0.877; p = 0.014). Older age at surgery (≥45 years) and multiple HCC nodules predicted an increased risk of late recurrence (HR, 3.270; 95{\%} CI, 1.296–8.251; p = 0.012; and HR, 3.146; 95{\%} CI, 1.396–7.089; p = 0.006). Decreased LSM also suggested decreased mortality (HR, 0.251; 95{\%} CI, 0.086–0.756; p = 0.045) along with baseline low aspartate aminotransferase-to-platelet ratio index (APRI) score (<1.5) (HR, 0.251; 95{\%} CI, 0.086–0.759; p = 0.041). Having early HCC recurrence (HR, 9.416; 95{\%} CI, 3.566–24.861; p < 0.001) and microvascular tumor invasion (HR, 3.191; 95{\%} CI, 1.188–8.568; p = 0.021) predicted increased mortality. Among HCC patients with liver cirrhosis under antiviral therapy, achieving low LSM (≤8 kPa) predicted reduced late HCC recurrence.",
author = "Lee, {Jung Il} and Lee, {Hyun Woong} and Kim, {Seung Up} and Ahn, {Sang Hoon} and Lee, {Kwan Sik}",
year = "2019",
month = "3",
doi = "10.3390/cancers11030425",
language = "English",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "3",

}

Follow-up liver stiffness measurements after liver resection influence oncologic outcomes of hepatitis-b-associated hepatocellular carcinoma with liver cirrhosis. / Lee, Jung Il; Lee, Hyun Woong; Kim, Seung Up; Ahn, Sang Hoon; Lee, Kwan Sik.

In: Cancers, Vol. 11, No. 3, 425, 03.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Follow-up liver stiffness measurements after liver resection influence oncologic outcomes of hepatitis-b-associated hepatocellular carcinoma with liver cirrhosis

AU - Lee, Jung Il

AU - Lee, Hyun Woong

AU - Kim, Seung Up

AU - Ahn, Sang Hoon

AU - Lee, Kwan Sik

PY - 2019/3

Y1 - 2019/3

N2 - The severity of liver fibrosis can be noninvasively evaluated by measuring liver stiffness (LS) using transient elastography. This study aimed to evaluate the prognostic value of achieving low liver stiffness measurement (LSM) in patients with cirrhosis confirmed from the resected liver due to hepatocellular carcinoma (HCC). A total of 184 patients that received curative surgery for HCC related to the hepatitis B virus at Barcelona Clinic Liver Cancer stage 0–A, and had a METAVIR fibrosis score of 4 were investigated. LSM significantly decreased after antiviral therapy during follow-up (p = 0.001), and achieving LSM ≤8 kilopascal (kPa) suggested a reduced risk of late recurrence (>12 months) (hazard ratio (HR), 0.519; 95% confidence interval (CI), 0.307–0.877; p = 0.014). Older age at surgery (≥45 years) and multiple HCC nodules predicted an increased risk of late recurrence (HR, 3.270; 95% CI, 1.296–8.251; p = 0.012; and HR, 3.146; 95% CI, 1.396–7.089; p = 0.006). Decreased LSM also suggested decreased mortality (HR, 0.251; 95% CI, 0.086–0.756; p = 0.045) along with baseline low aspartate aminotransferase-to-platelet ratio index (APRI) score (<1.5) (HR, 0.251; 95% CI, 0.086–0.759; p = 0.041). Having early HCC recurrence (HR, 9.416; 95% CI, 3.566–24.861; p < 0.001) and microvascular tumor invasion (HR, 3.191; 95% CI, 1.188–8.568; p = 0.021) predicted increased mortality. Among HCC patients with liver cirrhosis under antiviral therapy, achieving low LSM (≤8 kPa) predicted reduced late HCC recurrence.

AB - The severity of liver fibrosis can be noninvasively evaluated by measuring liver stiffness (LS) using transient elastography. This study aimed to evaluate the prognostic value of achieving low liver stiffness measurement (LSM) in patients with cirrhosis confirmed from the resected liver due to hepatocellular carcinoma (HCC). A total of 184 patients that received curative surgery for HCC related to the hepatitis B virus at Barcelona Clinic Liver Cancer stage 0–A, and had a METAVIR fibrosis score of 4 were investigated. LSM significantly decreased after antiviral therapy during follow-up (p = 0.001), and achieving LSM ≤8 kilopascal (kPa) suggested a reduced risk of late recurrence (>12 months) (hazard ratio (HR), 0.519; 95% confidence interval (CI), 0.307–0.877; p = 0.014). Older age at surgery (≥45 years) and multiple HCC nodules predicted an increased risk of late recurrence (HR, 3.270; 95% CI, 1.296–8.251; p = 0.012; and HR, 3.146; 95% CI, 1.396–7.089; p = 0.006). Decreased LSM also suggested decreased mortality (HR, 0.251; 95% CI, 0.086–0.756; p = 0.045) along with baseline low aspartate aminotransferase-to-platelet ratio index (APRI) score (<1.5) (HR, 0.251; 95% CI, 0.086–0.759; p = 0.041). Having early HCC recurrence (HR, 9.416; 95% CI, 3.566–24.861; p < 0.001) and microvascular tumor invasion (HR, 3.191; 95% CI, 1.188–8.568; p = 0.021) predicted increased mortality. Among HCC patients with liver cirrhosis under antiviral therapy, achieving low LSM (≤8 kPa) predicted reduced late HCC recurrence.

UR - http://www.scopus.com/inward/record.url?scp=85064351858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064351858&partnerID=8YFLogxK

U2 - 10.3390/cancers11030425

DO - 10.3390/cancers11030425

M3 - Article

AN - SCOPUS:85064351858

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 3

M1 - 425

ER -